Aldeyra Therapeutics Inc. (ALDX)
Aldeyra Therapeutics Statistics
Share Statistics
Aldeyra Therapeutics has 59.55M shares outstanding. The number of shares has increased by 1.11% in one year.
| Shares Outstanding | 59.55M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.22% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 57.82M |
| Failed to Deliver (FTD) Shares | 1.71K |
| FTD / Avg. Volume | 0.37% |
Short Selling Information
The latest short interest is 3.55M, so 5.95% of the outstanding shares have been sold short.
| Short Interest | 3.55M |
| Short % of Shares Out | 5.95% |
| Short % of Float | 6.13% |
| Short Ratio (days to cover) | 6.4 |
Valuation Ratios
The PE ratio is -5.51 and the forward PE ratio is -7.8.
| PE Ratio | -5.51 |
| Forward PE | -7.8 |
| PS Ratio | 0 |
| Forward PS | 5.6 |
| PB Ratio | 1.73 |
| P/FCF Ratio | -6.82 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Aldeyra Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.64, with a Debt / Equity ratio of 0.13.
| Current Ratio | 6.64 |
| Quick Ratio | 6.64 |
| Debt / Equity | 0.13 |
| Total Debt / Capitalization | 11.56 |
| Cash Flow / Debt | -1.94 |
| Interest Coverage | -20.66 |
Financial Efficiency
Return on equity (ROE) is -0.31% and return on capital (ROIC) is -31.59%.
| Return on Equity (ROE) | -0.31% |
| Return on Assets (ROA) | -0.25% |
| Return on Capital (ROIC) | -31.59% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -4.17M |
| Employee Count | 9 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 48.82% in the last 52 weeks. The beta is 1.43, so Aldeyra Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.43 |
| 52-Week Price Change | 48.82% |
| 50-Day Moving Average | 4.93 |
| 200-Day Moving Average | 4.65 |
| Relative Strength Index (RSI) | 51 |
| Average Volume (20 Days) | 457.46K |
Income Statement
| Revenue | n/a |
| Gross Profit | -262.78K |
| Operating Income | -42.79M |
| Net Income | -37.54M |
| EBITDA | -35.21M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.64 |
Balance Sheet
The company has 142.82M in cash and 15.66M in debt, giving a net cash position of 127.17M.
| Cash & Cash Equivalents | 142.82M |
| Total Debt | 15.66M |
| Net Cash | 127.17M |
| Retained Earnings | -394.26M |
| Total Assets | 117.32M |
| Working Capital | 99.57M |
Cash Flow
In the last 12 months, operating cash flow was -30.33M and capital expenditures 0, giving a free cash flow of -30.33M.
| Operating Cash Flow | -30.33M |
| Capital Expenditures | 0 |
| Free Cash Flow | -30.33M |
| FCF Per Share | -0.51 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ALDX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -12.72% |
| FCF Yield | -10.12% |
Analyst Forecast
The average price target for ALDX is $10, which is 98.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 98.8% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Scores
| Altman Z-Score | 0.31 |
| Piotroski F-Score | 2 |